Build a device plant that clears the audit.
Term and working capital finance for medical device manufacturing — disposables, implants, diagnostic kits, surgical instruments and electro-medical equipment — including clean rooms, tooling, sterilisation capacity and the quality system the regulation demands.
Regulatory class drives everything
Under the Medical Devices Rules, devices are classified A through D by risk, and the class determines your licensing pathway, your quality system obligations and the depth of testing and documentation required. A Class A dressing and a Class C implant are not comparable projects, and a credit team that understands the sector will ask about class before anything else.
Certification is a capital item, not an afterthought. ISO 13485 quality management certification, CDSCO manufacturing licence, and where you intend to export, CE marking or US FDA pathways, each carry consultancy, testing, documentation and audit costs, plus timelines measured in quarters. These belong in the project cost.
Sterilisation is a decision with real capital consequences. In-house ethylene oxide or gamma capacity is a substantial investment with its own regulatory and environmental compliance; outsourcing to a contract steriliser reduces capex but adds per-unit cost, logistics and dependence on a third party's capacity and validation. Lenders will ask which route you have chosen and want the reasoning.
Indicative pricing in 2026
Device manufacturing benefits from strong policy support for import substitution. Units with export orders or contracted offtake price at the sharp end.
Public Sector Banks
Tier-1 Private Banks
NBFCs & HFCs
What strengthens a device manufacturing file
Contracted offtake beats a market study
Device demand projections are hard for a credit team to test. An OEM supply agreement, a hospital group contract, a government tender award or an export order transforms the file from a projection into a receivable. Even a modest committed volume changes how the whole appraisal reads.
Certification timeline built into the moratorium
ISO 13485 audit, CDSCO licence and, for exports, CE or FDA pathways run in quarters, not weeks, and commercial sale cannot begin without them. A moratorium that ends at mechanical completion leaves you paying EMIs on a plant that is legally unable to sell.
Import content and forex exposure
Tooling, moulds, specialised polymers and electronic components are frequently imported, often on letters of credit. Both the landed cost and the timeline are exposed to currency and shipping variability. Structure the import leg deliberately through trade finance rather than absorbing it in the term loan.
Documents required
Incomplete files cause most multi-week delays. We assemble the full set upfront, in the order credit teams read it.
KYC & constitution
- PAN & Aadhaar of all promoters / partners / directors
- Certificate of incorporation, MOA-AOA or partnership deed
- Board resolution or partners' authority letter
- GST registration & trade licence
Regulatory & technical
- CDSCO manufacturing licence or application, with device class
- ISO 13485 certification or gap assessment and plan
- Detailed project report with layout and clean-room classification
- Machinery, tooling and sterilisation equipment quotations
- Pollution consent, fire NOC and factory licence
- Export certifications — CE, FDA — where applicable
Commercial & financial
- 3 years audited financials, where an existing entity
- Supply agreements, tender awards or export orders
- Product-wise costing and capacity utilisation projections
- 12 months' bank statements and GST returns
Related facilities & deep-dive guides
Every facility below is placed through the same 80+ lender panel. The long-form guides carry the working numbers, worked examples and lender-by-lender detail.
Frequently Asked Questions
The questions our advisory desk is asked most often about Medical Device Manufacturing Loan.
It changes the project, and therefore the file. Class C and D devices carry heavier licensing, testing and quality-system obligations, longer approval timelines and higher compliance capex than Class A or B.
Lenders do not refuse higher classes, but they expect a longer moratorium and more detailed regulatory planning. Be explicit about class in the project report.
In-house gives you control, capacity certainty and better unit economics at scale, at the cost of significant capex and its own environmental and regulatory compliance burden. Outsourcing conserves capital but adds per-unit cost and third-party dependence.
At start-up volumes outsourcing is often the sound choice, with in-house capacity funded as a phase two once volumes justify it. Present it as a reasoned decision, not a default.
Partly. Lenders will usually accept certification, validation and regulatory consultancy as legitimate project cost components, though they may fund a lower percentage of them than of plant and machinery.
What matters more is that they are in the estimate at all. Files that omit them under-fund the project at exactly the point where there is no revenue to fall back on.
Considerably. A confirmed export order or a supply agreement with an established OEM converts a demand projection into visible cash flow, which is the hardest thing to establish in a greenfield device file.
It also opens export credit and pre-shipment finance alongside the term loan — see trade and export finance.
Yes. Import substitution in medical devices has been a policy priority, with support through production-linked incentives, medical device park schemes and general MSME instruments such as CGTMSE and CLCSS where applicable.
Scheme windows and terms change, so check the current position through our government and PSU schemes desk before locking the funding structure.
Tell us what you need. We'll do the running around.
Share a few details and a CreditCares expert will call you back to map your eligibility and shortlist the right lenders — at no cost.